Alumis Inc (NASDAQ:ALMS) IPO will take place June, 28 on the NASDAQ exchange under the ticker ALMS.

The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on December 25, 2024.

See also: Benzinga IPO Calendar

About Alumis Inc

Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases. Leveraging its precision data analytics and a multi-platform approach, Alumis is advancing a pipeline of oral therapies designed to address immune dysfunction

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.